Immunological effects of hypomethylating agents.

about

Immunotherapy With Human Gamma Delta T Cells-Synergistic Potential of Epigenetic Drugs?Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

P2860

Q55030400-B3AA5CEE-B0A9-459A-9521-D0B6728F44F6 Q55364989-4528CDEA-49E5-4C2C-A396-F420774E14C3

P2860

Immunological effects of hypomethylating agents.

Item

http://www.wikidata.org/entity/Q48229616

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Immunological effects of hypomethylating agents.

@en

Immunological effects of hypomethylating agents.

@nl

type

Item

label

Immunological effects of hypomethylating agents.

@en

Immunological effects of hypomethylating agents.

@nl

prefLabel

Immunological effects of hypomethylating agents.

@en

Immunological effects of hypomethylating agents.

@nl

P1476

Immunological effects of hypomethylating agents.

@en

P2093

Karolyn A Oetjen

http://www.w3.org/2001/XMLSchema#string

Katherine E Lindblad

http://www.w3.org/2001/XMLSchema#string

Meghali Goswami

http://www.w3.org/2001/XMLSchema#string

P2860

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers

DNA methylation maintains allele-specific KIR gene expression in human natural killer cells

The evolution of natural killer cell receptors

Evaluation of current cancer immunotherapy: hemato-oncology

DNMT3A Mutations in Acute Myeloid Leukemia

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

P304

745-752

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1346470

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christopher S Hourigan

P577

2017-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28644756

http://www.w3.org/2001/XMLSchema#string

P921

immunology

P932

6071309

http://www.w3.org/2001/XMLSchema#string

Immunological effects of hypomethylating agents.

about

P2860

P2860

Immunological effects of hypomethylating agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932